Objective:To research the development status of medical robot industry at home and abroad at present,and analyze the development dynamics,technological advances,market trends,and existing challenges of this field,so as to promote the long-term development of health industry of Chinese population. Methods:The systematic review was adopted. According to declaration standards of preferred reporting items for systematic reviews and meta-analyses (PRISMA) of systematic evaluation and meta-analysis in 2020,the relevant research literatures of medical robots from January 10th 2015 to January 10th 2024 was retrieved. The CNKI was used as the data source of Chinese literature,and the Web of Science (WOS) of American was used as data resource of English literature. The preliminary screening of 245 research papers were screened according to the inclusion and exclusion criteria. Finally,the screened 194 literatures were used as core samples to conduct qualitative analysis in industrial development situation,development scale and growth trend,policy and requirement of development and existing problem of medical robots. Results:The development of medical robots in China was later than that in foreign countries. As a result,the industrial collaborative innovation mechanism had not yet been fully established,and the core technique innovation capability was relatively weak. In recent years,the size of the market of medical robots in China has continuously expanded,and we had obtained significant breakthroughs in the development and application of single-port robots and micro-robots. Under the guidance and support of government policies,China's enterprises of medical robot had achieved critical technical advancements in the research and development of core components,and the degree of autonomy of industrial chain continuously was improved. As the advanced intelligent manufacturing,the technique of medical robot had played an increasingly important role in medical services and other fields in China. Conclusion:The industry of medical robots in China is currently in a period of strategic opportunities driven by high-speed growth and innovation. But it also facing a series of challenges such as upgrading core technique,optimizing industrial structures and intensifying international competition. In the future,China must further strengthen basic research,and enhance original innovation capabilities,and strengthen the integration of upstream and downstream of the industrial chain,so as to realize sustainable development with high quality in the industry of medical robots in China.

Objective:To research the development status of medical robot industry at home and abroad at present,and analyze the development dynamics,technological advances,market trends,and existing challenges of this field,so as to promote the long-term development of health industry of Chinese population. Methods:The systematic review was adopted. According to declaration standards of preferred reporting items for systematic reviews and meta-analyses (PRISMA) of systematic evaluation and meta-analysis in 2020,the relevant research literatures of medical robots from January 10th 2015 to January 10th 2024 was retrieved. The CNKI was used as the data source of Chinese literature,and the Web of Science (WOS) of American was used as data resource of English literature. The preliminary screening of 245 research papers were screened according to the inclusion and exclusion criteria. Finally,the screened 194 literatures were used as core samples to conduct qualitative analysis in industrial development situation,development scale and growth trend,policy and requirement of development and existing problem of medical robots. Results:The development of medical robots in China was later than that in foreign countries. As a result,the industrial collaborative innovation mechanism had not yet been fully established,and the core technique innovation capability was relatively weak. In recent years,the size of the market of medical robots in China has continuously expanded,and we had obtained significant breakthroughs in the development and application of single-port robots and micro-robots. Under the guidance and support of government policies,China's enterprises of medical robot had achieved critical technical advancements in the research and development of core components,and the degree of autonomy of industrial chain continuously was improved. As the advanced intelligent manufacturing,the technique of medical robot had played an increasingly important role in medical services and other fields in China. Conclusion:The industry of medical robots in China is currently in a period of strategic opportunities driven by high-speed growth and innovation. But it also facing a series of challenges such as upgrading core technique,optimizing industrial structures and intensifying international competition. In the future,China must further strengthen basic research,and enhance original innovation capabilities,and strengthen the integration of upstream and downstream of the industrial chain,so as to realize sustainable development with high quality in the industry of medical robots in China.

Objective:To evaluate the clinical efficacy and safety of fecal microbiota transplantation(FMT)for the treatment of chronic functional constipation in the elderly.Methods:A total of 33 elderly patients with chronic functional constipation were included and given three sessions of FMT.Changes in fecal characteristics, constipation, mood and quality of life in these patients were evaluated using the Bristol stool form scale(BSFS), the constipation assessment scale(CAS), patient assessment of constipation symptoms(PAC-SYM), the Zung self-rating anxiety scale(SAS), the Zung self-rating depression scale(SDS), and the patient assessment of constipation quality of life(PAC-QOL)before and 12 weeks after treatment.The clinical efficacy was based on comparison between pre-and post-treatment results for each patient.Results:Clear improvement was achieved in 33 patients 12 weeks after treatment, compared with before transplantation.Post-treatment scores of the constipation assessment scale and symptom self-assessment questionnaire for patients with constipation were(8.9±1.2)scores and(26.5±2.4)scores, respectively, significantly lower than pre-transplantation scores of(12.2±1.1)scores and(32.4±2.4)scores( t=15.034, 13.904, both P<0.001). Similarly, post-treatment scores were also lower than pre-transplantation levels for the self-rating anxiety scale[(50.4±8.4)scores vs.(57.5±9.0)scores, t=10.333, P<0.001], the self-rating depression scale[(50.6±8.4)% vs.(55.0±10.5)%, t=5.301, P<0.001], and self-assessment questionnaire for quality of life[(88.2±7.3)scores vs.(103.7±7.3)scores, t=23.300, P<0.001]. Conclusions:FMT can improve fecal characteristics and constipation symptoms, relieve anxiety and depression, improve the quality of life, and provide a new option for the treatment for elderly patients with chronic functional constipation.

Objective To establish an anti-hepatitis E virus (HEV) enzyme-linked immunosorbent assay (ELISA) one-step assay based on seven glutathione S-transferase (GST)-fusion recombinant proteins derived from different HEV genotypes and subtypes. Methods Concentration of the coating antigen was optimized by block titration. The cut-off values were determined for anti-HEV IgG and IgM, respectively. Assay sensitivity, specificity and reproducibility were investigated using samples with confirmed anti-HEV positive. Results An optimal concentration of mixture of recombinant proteins (Mix166) was 1.5 mg/L for antigen coating. Coefficient of variations (CV) of anti-HEV within-run and between-run were 8.67% and 10.85%, respectively. CV of anti-HEV IgM within-run and between-run were 4.56% and 5.99%, respectively. Positive rates of anti-HEV IgG and IgM were both 94% for 50 HEV-polymerase chain reaction (PCR) positive sera tested with the one step assay. Using one-step assay to detect 674 serum samples from healthy people, 52 samples were found anti-HEV IgG positive and 3 samples were anti-HEV lgM positive. A series of serum specimens collected at different time points until 76 weeks from a chimpanzee challenged with HEV Mexican strain were anti-HEV IgM positive during week 1--6 and anti-HEV IgG positive during week 2--76 determined by the one step ELISA. However, import ELISA kits were lack of both the IgM and lgG reactivity to all of the serial chimpanzee sera. Conclusions The sensitivity and specificity of anti-HEV ELISA one-step assay based on the Mix166 antigen are high and could be used for the diagnosis of HEV infection.